We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Inspiration Healthcare Group Plc | LSE:IHC | London | Ordinary Share | GB00BXDZL105 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 31.00 | 30.00 | 32.00 | 31.00 | 30.30 | 31.00 | 1,430 | 08:00:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Home Health Care Services | 41.23M | 272k | 0.0040 | 77.50 | 21.14M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/10/2023 14:48 | Register for the seminar mentioned in the previous post (which includes a presentation from IHC) here: | timbo003 | |
14/10/2023 11:42 | ShareSoc is holding its first hybrid event in London on 19th Oct. Hear from Inspiration Healthcare Group (IHC) and other healthcare companies like Tristel Plc (TSTL), Creo Medical Group (CREO), Abingdon Health (ABDX) and GENincode (GENI). Attend in-person or online.📍 | sharesoc | |
11/10/2023 11:18 | gopher - I've emailed the IHC PR company about share price concerns and suggested BOD buy some shares etc to show some confidence in business.. | lammylover | |
10/10/2023 17:07 | I think I would prefer to see a buyback programme initiated here to mop up weak holders. I don't see this as a confidence issue that director buys would soothe. Leaving the stock market is rarely to investors benefit in these situations as buyers usually have the inside track. NASDAQ listing is the ultimate prize. | gopher | |
09/10/2023 12:41 | Shares large and particularly small getting battered at present by global events and fears. PIs just putting money into bank accounts for their 5% guaranteed return. Its making some AIM stocks look ridiculously undervalued and surely ripe for a takeover (and we are seeing plenty of private equity doing just that) IHC could do with Director buys to support the share price. Personally I'd be happy with a takeover here and someone who can deliver value from what should be easy to get big contract wins on what is non discretionary spending for hospitals etc. | lammylover | |
09/10/2023 12:13 | Latest investors meet presentation was positive overall. Financials slowly improving and emphasis on sales opportunities including dip into us market. Little interest in the company but continued share price decline looks unwarranted. | gopher | |
21/9/2023 16:12 | From memory when I visited the company prior to covid and way before the SLE acquisition the directors explained they designed their own products but sub-contracted the manufacturing to a company in Austria. I agree it's possible they are now suffering from growing pains post the SLE acquisition and from dealing with the move to new premises. | lindowcross | |
04/9/2023 10:55 | Just catching up. I have owned this for a while. This is a poor, early and big miss of a self-selected target. I have not seen Liberum note, but crudely appears to be a £3m revenue miss at a GM of 48%, so c. £1.5m profit hit, but seems to be £1.2m in broker's estimate. IHC has just appointed new brokers and PR advisers to generate institutional interest that could include supporting acquisitions. The one thing they could not afford to do was “miss their numbers”. I think there are some fundamental problems. Before the SLE acquisition, the group was a distributor of others’ products into the UK and Eire market. The acquisition added the complexity of manufacturing and worldwide distribution. It seems this has been too much for the management team: lack of controls led to a working capital cash suck (that is slowly unwinding under an interim and now a new CFO); they overspent (£1-2m?) on the new facility that has numerous vanity features, and their reporting/forecastin There needs to be change. The chair has been involved since 2001 and since the float in 2015. A new, possibly exec chair, with Danagher/GE sector/ops experience should come in. That chair should have a wide remit to review the strategy and team competency. Four non-execs is probably at least one too many for a company this size and, given the finance issues, the finance related NED should also step down. That should allow the appointment to be cost neutral. I wonder how active the institutions led by BGF will be - it is very small. I still think there is value in IHC’s position in neonatal distribution and equipment. On the equipment side, SLE’s automated oxygen control algorithms and equipment appear quite unique. The upside is US approval for its system. Even if that does not happen, the business should be cash generative and I suspect trade or PE would pay more than the year end EV (where I expect the working capital to swing the other way to turn net debt into a cash position). I will hold for a while longer. | mtioc | |
01/9/2023 09:39 | Sub 40 before I'd be interested | swerves1 | |
31/8/2023 17:19 | Swerves - assuming you are looking to buy in, hence hanging round and posting here. What price are you looking to buy in? Sub 40p?? | lammylover | |
31/8/2023 16:43 | A big dip today as I suspected. They will struggle to get any new investors for a while after this | swerves1 | |
31/8/2023 13:32 | tax will be offset, one way or another. Bottom line is its still a profitable business selling non discretionary items. | lammylover | |
31/8/2023 13:16 | Lammy - think you need to tax that PBT before you do a P/E calc... Eric | pireric | |
31/8/2023 12:12 | Edit - should say NOT stupidly high for what are in essence essential items | lammylover | |
31/8/2023 12:10 | 68.2m shares at 47p/share is mkt cap of £32m plus £2.1m debt. If IHC make £2.4m PBT this year then p/e at 14.2x. Slightly higher than I would like, but stupidly high for what are in essence, essential items for NHS etc. Share price may fall back a bit more, but margins improving on core products (neo natal baby equipment and ventillators) should ensure H2 is solid. A couple of decent sized contract wins will soon engage PIs again to push this north of 50p. Paul Hill in Stockopedia rated this a buy on 26.6.23 with a target of 84p. I'm at average 48.4p and happy to sit on these for next year for recovery in growth and share price. | lammylover | |
31/8/2023 11:26 | I was holding for a recovery in share price here having bought in at much higher level. Overall not a great update as would like to see revenue growing to re establish credentials as a growth company now relocation disruption is behind them. | gopher | |
31/8/2023 09:45 | Yes this has further to drop | swerves1 | |
31/8/2023 08:48 | Assume you guys are all looking for cheap shares here, hence negative comments? Looks like PIs are sitting on hands here, though - no flurry of selling activity. Shares cheap enough already IMO and should rise into H2 results if margins continue to improve and IHC can deliver some contract wins. | lammylover | |
31/8/2023 08:34 | Liberum have £2.4m pbt reduced from £3.6m for FY24 so a 34% miss. They've also shaved FY25 by 16%. Edit: repeating Hastings post above -soz | cockerhoop | |
31/8/2023 08:27 | Broker note issued this morning | hastings | |
31/8/2023 07:53 | Where's the PBT figures? I didn't see any in the update. Rev flat, margins improved. Debt reduced by £1.7m. | lammylover | |
31/8/2023 07:37 | Not good. Expect the share price will take a big dip today | swerves1 | |
31/8/2023 07:36 | Been keeping an eye on this ex holding, but a big drop in forecast PBT from £3.6m to £2.4m. | hastings | |
31/8/2023 07:11 | Profit warning | scepticalinvestor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions